CHIGENOVO key facts
as of Oct 2026- Developer of clinical genetic diagnosis, fertility prevention and gene therapy drug for hereditary eye diseases.
- CHIGENOVO is valued at approximately $110.4M as of Oct 2026 (last reported valuation).
- It has raised $41.0M; the latest was Later Stage VC in Sep 2025.
- Notable investors include Cowin Capital, Puhua Capital, Lapam Capital, Lotus Lake Ventures, Huayi Capital — 10 tracked in total.
- Status: Privately Held (backing).
CHIGENOVO's last reported valuation, Mar 2022. Nothing priced has surfaced since.
- ·Watch CHIGENOVO: the Monday email on marks, rounds and moves
CHIGENOVO funding rounds
No funding rounds for CHIGENOVO are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
CHIGENOVO valuation
CHIGENOVO's last reported valuation was $110 million in Mar 2022. No priced round, secondary trade or fund mark has surfaced since.
CHIGENOVO investors
10 investors are on record for CHIGENOVO, including Cowin Capital, Puhua Capital, Lapam Capital and Lotus Lake Ventures. By type, the record holds 4 venture capital firms, 1 family office and 1 growth equity firm.
About CHIGENOVO
Developer of clinical genetic diagnosis, fertility prevention and gene therapy drug for hereditary eye diseases. The company specializes in developing ophthalmic gene therapy drugs backed by accurate gene diagnosis, providing reliable ophthalmic gene pharmaceuticals for the public.
- Sector
- Healthcare
- HQ
- Beijing, China
- Founded
- 2016
- Website
- chinagene.cc/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.